Sluydts 2016.

Study characteristics
Methods	cRCT Unit of randomization: cluster made up by individual villages or a group of closely located villages ICC: not reported, retrospectively calculated: 0.0294 Trial duration: 20 months
Participants	Adults or children living in malaria endemic regions High risk population (forest workers) Endemic region for P vivax Participants not screened for hypnozoites
Interventions	Topical repellent: picaridin (KBR3023) Controls: no treatment Picaridin 10% for children < 10 years, and Picaridin 20% in individuals ≥ 10 years Co‐interventions: LLINs Treatment arms: Intervention: 49 clusters, 57 villages (5642 households, 25,051 individuals) Controls: 49 clusters, 56 villages (5287 households, 23,787 individuals)
Outcomes	Malaria case incidence: new cases of clinical malaria (caused by Plasmodium spp.) confirmed through blood smears or RDTs Incidence of recorded adverse events (including skin irritation, local pain, eye irritation, irritation of upper airways, nausea, vomiting, headaches, dizziness or confusion, allergic or anaphylactic reactions, and systemic toxicity) Malaria prevalence Adherence to regular usage of the intervention (defined based on recommendations provided by researchers to participants of individual trials)
Notes	Carried out in Cambodia Funded by: Bill and Melinda Gates Foundation, Belgian Cooperation

cRCT: cluster‐randomized controlled trial; ICC: intra‐class correlation coefficient; LLIN: long‐lasting insecticide‐treated nets; RDTs: rapid diagnostic tests